Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia

Somedeb Ball, Akriti G Jain, Parth C. Patel, Chen Wang, Luis E. Aguirre, Mohammad O Hussaini, Onyee Chan, Seongseok Yun, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman

Blood (2022) 140 (Supplement 1): 6282–6284.

https://doi.org/10.1182/blood-2022-170442

Published: 2022

Journal Articles

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Onyee Chan, Najla Al Ali, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Hammad Tashkandi, Ling Zhang, Mohammad O Hussaini, Seongseok Yun, Andrew Kuykendall, Eric Padron, Gail J. Roboz, Pinkal Desai, Rami S. Komrokji, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman

Blood (2022) 140 (Supplement 1): 3435–3437.

https://doi.org/10.1182/blood-2022-171197

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Retrospective Analysis of Minimal Residual Disease Testing By High Throughput Immunosequencing Versus High Sensitivity Flow Cytometry and qPCR in B-Lymphoblastic Leukemia

Omar Fathalla, Anwar Khan, Nagehan Pakasticali, Bijal D. Shah, Mohammad O Hussaini

Blood (2021) 138 (Supplement 1): 4476.

https://doi.org/10.1182/blood-2021-154383

Published: 2021

Journal Articles

Clinical Characteristics and Outcome of Patients with EZH2 - Mutant Myelodysplastic Syndromes

Somedeb Ball, Luis E. E. Aguirre, Akriti G Jain, Mohammad O Hussaini, Najla Al Ali, Sara Marie Tinsley-Vance, Onyee Chan, Andrew T. Kuykendall, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman, Eric Padron, Rami S. Komrokji

Blood (2021) 138 (Supplement 1): 1531.

https://doi.org/10.1182/blood-2021-153465

Published: 2021

Journal Articles

In Depth Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases

Robert S. Ohgami, Phyu Aung, Alejandro Ariel Gru, Mohammad O Hussaini, Christiane Querfeld, Kelou Yao, Corinn Small, Sumanth Gollapudi, David L Jaye, Sa A Wang, Sheeja T Pullarkat, Tracy I. George

Blood (2021) 138 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2021-151694

Published: 2021

Journal Articles

Retrospective Analysis of Minimal Residual Disease Testing By High Throughput Immunosequencing Versus High Sensitivity Flow Cytometry in Multiple Myeloma

Anwar Khan, Nagehan Pakasticali, Omar Fathalla, Taiga Nishihori, Mohammad O Hussaini

Blood (2021) 138 (Supplement 1): 1625.

https://doi.org/10.1182/blood-2021-154418

Published: 2021

Journal Articles

Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes

Amy Song, Omar Altabbakh, BS, David A. Sallman, MD, Eric Padron, MD, Chetasi Talati, MD, Mohammad O Hussaini, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142615

Published: 2020

Journal Articles

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Mohammad O Hussaini, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD MS, David A. Sallman, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140885

Published: 2020

Journal Articles

U2AF1 and EZH2 Mutations Are Associated with Non-Immune Hemolytic Anemia in Myelodysplastic Syndromes

Rami S. Komrokji, MD, Najla Al Ali, M.Sc, Mohammad O Hussaini, MD, David A. Sallman, MD, Dana Elise Rollison, PhD, Eric Padron, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139710

Published: 2020

Journal Articles

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

Pukhraz Basra, MBBS, David Gajzer, MD, Mohammad O Hussaini, MD, Hailing Zhang, MD, Lynn C. Moscinski, MD, Eric Padron, MD, David A Sallman, MD, Rami S. Komrokji, MD, Ling Zhang, MD, Jinming Song, MD PhD

Blood (2019) 134 (Supplement_1): 5428.

https://doi.org/10.1182/blood-2019-132070

Published: 2019

Journal Articles

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Mohammad O Hussaini, MD, Jinming Song, MD PhD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Sayeef Mirza, MDMPH, Ling Zhang, MD

Blood (2019) 134 (Supplement_1): 5442.

https://doi.org/10.1182/blood-2019-128997

Published: 2019

Journal Articles

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

David M Swoboda, MD, Jung-Hoon Lee, MD, Onyee Chan, MD, Rami S. Komrokji, MD, Najla Al Ali, M.Sc, Eric Padron, MD, Alan F. List, MD, Mohammad O Hussaini, MD, Jinming Song, MD PhD, David A Sallman, MD

Blood (2019) 134 (Supplement_1): 4244.

https://doi.org/10.1182/blood-2019-124772

Published: 2019

Journal Articles

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Mohammad O Hussaini, MD, Jaya Srivastava, PhD, Lik Wee Lee, PhD, Taiga Nishihori, MD, Bijal Shah, MD, Melissa Alsina, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD PhD, Kenneth H. Shain, MD PhD

Blood (2019) 134 (Supplement_1): 4654.

https://doi.org/10.1182/blood-2019-129846

Published: 2019

NARROW

Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Retrospective Analysis of Minimal Residual Disease Testing By High Throughput Immunosequencing Versus High Sensitivity Flow Cytometry and qPCR in B-Lymphoblastic Leukemia

Clinical Characteristics and Outcome of Patients with EZH2 - Mutant Myelodysplastic Syndromes

In Depth Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases

Retrospective Analysis of Minimal Residual Disease Testing By High Throughput Immunosequencing Versus High Sensitivity Flow Cytometry in Multiple Myeloma

Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

U2AF1 and EZH2 Mutations Are Associated with Non-Immune Hemolytic Anemia in Myelodysplastic Syndromes

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only